SEPTODONT INC
GenericsSEPTODONT INC is a generic drug manufacturer focused on Gastroenterology.
SEPTODONT INC's Key Drugs
SEPTODONT INC's core commercial portfolio centers on DYCLOPRO, PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, spanning Gastroenterology — its most strategically important drugs approved in the last 15 years.
SEPTODONT INC's Recent FDA Approvals
New NDA/BLA approvals for SEPTODONT INC over the last two years — novel drugs only, excluding generics and label supplements.
SEPTODONT INC's Therapeutic Areas
SEPTODONT INC's approved drugs and pipeline span 1 therapeutic area, led by Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SEPTODONT INC's Top Competitors
SEPTODONT INC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SEPTODONT INC Pipeline Snapshot
Active clinical trials for SEPTODONT INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DYCLOPRO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Gastroenterology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1972-10-17
- Latest
- 2019-11-26
- Applications
- 8